Evotec and Harvard unite on antibiotics

Germany-based Evotec is to collaborate with US-based Harvard University to discover and developing novel anti-bacterial agents in the hope of creating a new class of antibiotics.

Frankfurt-listed drug discovery business Evotec will harness the power of its comprehensive drug discovery infrastructure and expertise, using assays, chemical starting points and x-ray crystallographic tools licensed from Harvard.

Researchers at Harvard and Evotec will collaboratively identify small molecule inhibitors of bacterial cell wall synthesis. They will specifically target peptidoglycan biosynthesis (PGB), a pathway…